李诗良-全讯国际

中文 | english



李诗良,博士

副教授,硕士生导师

邮箱:shiliangli@ecust.edu.cn

地址:上海市徐汇区梅陇路130号华东理工大学实验18516

  

教育背景

(1)2011-09 至 2016-06,华东理工大学,药学, 博士(导师:李洪林 教授)
(2)2007-09 至 2011-06,华东理工大学,制药工程,学士(导师:李洪林 教授)


科研与学术工作经历

(1)2019-08 至今,华东理工大学,药学院,副教授

(2)2018-11 至 2019-07,华东理工大学,药学院,特聘副研究员

(3)2016-07 至 2018-10,华东理工大学,博士后(导师:徐玉芳 教授


研究方向

(1)基于结合热/动力学的药物设计

(2)人工智能药物设计方法开发与应用


个人简介

 主要聚焦导致药物临床失败的关键问题如药效不足和安全性差等,通过发展药物设计新方法和新技术,针对危及人民生命健康的重大疾病,开展应用研究,发现多类新型强效的候选药物。取得的成绩:1)自主发展新的药物设计方法及程序5套,获软件800全讯白菜官方网站的版权2项;2)通过开发及使用多策略药物设计方法,针对重大疾病如癌症、糖尿病及自身免疫性疾病相关的重要靶标进行系统性药物设计研究,发现多类骨架新颖的活性化合物和先导结构,参与设计的分子中现已有31类和12类候选新药完成技术成果转化,其中2个进入临床研究;3)在protein & cell, apsb, j. med. chem.等专业期刊上发表sci论文43篇,h指数为12,总他引600多次;包括第一/通讯论文22篇,其中一区论文6篇,二区论文6篇,if>510篇;4)申请发明专利14项,转国际pct专利5项;中国授权专利4项,其中1件专利在国外6个国家和地区授权;5)主持国家、省部级科研项目5项,包括国自然面上和青年项目、上海市“扬帆”计划、中国博士后面上一等资助等。


承担科研项目

(1)国家自然科学基金委员会,专项项目,82150208,2022-01-01至2024-12-31,280万元,在研,参与

(2)国家自然科学基金委员会,面上项目,82173690,2022-01-01至2025-12-31,55万元,在研,主持

(3)国家自然科学基金委员会,青年科学基金项目,81803437,2019-01-01至2021-12-31,21万元,在研,主持

(4)临港实验室,“求索杰出青年计划”开放课题,lg-qs-202206-02,2022-01 至 2024-12,300万元,在研,主持

(5)上海市科委,青年科技英才扬帆计划,18yf1405100,2018-05 至 2021-04,20万元,结题,主持

(6)科技部,国家“重大新药创制”科技重大专项子课题,2018zx09711002-001-009,2018-01  至 2020-12,241.07万元,结题,参与

(7)中国博士后科学基金会,面上资助,2016m600290,2016-11 至 2018-07,8万元,结题,主持

 

代表性论文(第一作者或通讯作者)

(1) xiong, rui#; zhang, leike#; li, shiliang#;  sun, yuan; ding, minyi; wang, yong; zhao, yongliang; wu, yan; shang,  weijuan; jiang, xiaming; shan, jiwei; shen, zihao; tong, yi; xu, liuxin;  chen, yu; liu, yingle; zou, gang; lavillete, dimitri; zhao, zhenjiang;  wang, rui; zhu, lili; xiao, gengfu; lan, ke; li, honglin*; xu, ke*; novel  and potent inhibitors targeting dhodh are broad-spectrum antivirals  against rna viruses including newly-emerged coronavirus sars-cov-2, protein & cell, 2020, 11(10): 723-739.(封面文章)

(2) zeng, fanxun#; li, shiliang#;  yang, guantian#; luo, yating#; qi, tiantian; liang, yingfan; yang, tingyuan; zhang, letian; wang, rui*; zhu, lili*; li, honglin*; xu, xiaoyong*  ; design, synthesis, molecular modeling, and biological  evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis., acta pharmaceutica sinica b, 2020, 11(3): 795-809.(封面文章)

(3) li, shiliang#;  qin, chun#; cui, shichao#; xu, hongling; wu, fangshu; wang, jiawei; su,  mingbo; fang, xiaoyu; li, dan; jiao, qian; zhang, ming; xia, chunmei;  zhu, lili; wang, rui; li, jia; jiang, hualiang; zhao, zhenjiang*; li,  jingya*; li, honglin*; discovery of a natural-product-derived preclinical candidate for once-weekly treatment of type 2 diabetes, journal of medicinal chemistry, 2019, 62(5): 2348-2361.(封面文章)

(4) yuan,  yuan#; xu, junpeng#; jiang, lei#; yu, kangjie; ge#, yuanyuan; li, mingyang;  he, huan; niu, qiqi; shi, xiayu; fan, linni; chen, zhuo; zhao,  zhenjiang; li, shiliang*; xu, yufang*; wang, zhe*; li, honglin*; discovery,  optimization, and structure-activity relationship study of novel and  potent rsk4 inhibitors as promising agents for the treatment of  esophageal squamous cell carcinoma, journal of medicinal chemistry, 2021, 64(18): 13572-13587.

(5) li shiliang#;  xu hongling#; cui shichao#; wu fangshu; zhang youli; su mingbo; gong  yinghui; qiu shaobing; jiao qian; qin chun; shan jiwei; zhang ming; wang  jiawei; yin qiao; xu minghao; liu xiaofeng; wang rui; zhu lili; li jia;  xu yufang; jiang hualiang; zhao zhenjiang*; li jingya*; li honglin*; discovery and rational design of natural-product-derived  2-phenyl-3,4-dihydro-2h-benzo[f]chromen-3-amine analogs as novel and  potent dipeptidyl peptidase 4 (dpp-4) inhibitors for the treatment of  type 2 diabetes, journal of medicinal chemistry, 2016, 59(14): 6772-6790.

(6) li shiliang#; zhou yi#; lu weiqiang#; zhong ye; song wenlong; liu kangdong; huang jin*; zhao zhenjiang; xu yufang; liu xiaofeng*; li honglin ; identification  of inhibitors against p90 ribosomal s6 kinase 2 (rsk2) through  structure-based virtual screening with the inhibitor-constrained refined  homology model, journal of chemical information and modeling, 2011, 51(11): 2939-2947.

(7) yang gui xiang; ge song lan; wu yan; huang jin; li shiliang*; wang rui*; ma lei *; design,  synthesis and biological evaluation of 3-piperazinecarboxylate  sarsasapogenin derivatives as potential multifunctional anti-alzheimer  agents, european journal of medicinal chemistry, 2018, 156: 206-215.

(8) li, shiliang; cai, chaoqian; gong, jiayu; liu, xiaofeng; li, honglin*; a fast protein binding site comparison algorithm for proteome-wide protein function prediction and drug repurposing, proteins: structure, function, and genetics, 2021, 89(11): 1541-1556.(封面文章)

(9) wang, disha; liu, wenjun; shen, zihao; jiang, lei; wang, jie; li, shiliang*; li, honglin*; deep learning based drug metabolites prediction, frontiers in pharmacology, 2020, 10: 0-1586.

(10) luo, na; fang, xiaoyu; su, mingbo; zhang, xinwen; li, dan; li, honglin; li, shiliang*; zhao, zhenjiang*; design, synthesis and sar studies of novel and potent dipeptidyl peptidase 4 inhibitors, chinese journal of chemistry, 2021, 39(1): 115-120.

(11) he gaoqi; gong bojie; li jianqiang; song yiping; li shiliang*; lu xingjian *; an improved receptor-based pharmacophore generation algorithm guided by atomic chemical characteristics and hybridization types, frontiers in pharmacology, 2018, 9: 0-1463.

(12) meng jiajia#; li shiliang#; liu xiaofeng; zheng mingyue; li honglin*; rd-metabolizer:  an integrated and reaction types extensive approach to predict  metabolic sites and metabolites of drug-like molecules, chemistry central journal, 2017, 11: 0-65.

(13) li shiliang#;  luan guoqin#; ren xiaoli#; song wenlin; xu liuxin; xu minghao; zhu  junsheng; dong dong; diao yanyan; liu xiaofeng; zhu lili; wang rui; zhao  zhenjiang*; xu yufang*; li honglin*; rational design of  benzylidenehydrazinyl-substituted thiazole derivatives as potent  inhibitors of human dihydroorotate dehydrogenase with in vivo  anti-arthritic activity, scientific reports, 2015, 5: 0-14836.

(14) li, qiannan#; zhang, tao#; li, shiliang#;  tong, linjiang; li, junyu; su, zhicheng; feng, fang; sun, deheng; tong,  yi; wang, xia; zhao, zhenjiang; zhu, lili; ding, jian; li, honglin*;  xie, hua*; xu, yufang *; discovery of potent and noncovalent reversible egfr kinase inhibitors of egfr(l858r/t790m/c797s), acs medicinal chemistry letters, 2019, 10(6): 869-873.

(15) qiu che#; yuan zhen#; he zhiyan; chen huiwen; liao yue; li shiliang*; zhou wei*; song zhongchen*; lipopolysaccharide  preparation derived from porphyromonas gingivalis induces a weaker  immuno-inflammatory response in bv-2 microglial cells than escherichia  coli by differentially activating tlr2/4-mediated nf-κb/stat3 signaling  pathways, frontiers in cellular and infection microbiology, 2021, 11.





网站地图